Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24701146 | 0.89 | PNP (0.42) | PNPTYMS | |
| SCHEMBL19929241 | 0.88 | PNP (0.48) | PNPTYMS | |
| SCHEMBL24700868 | 0.86 | PNP (0.47) | PNPTYMS | |
| SCHEMBL20202021 | 0.84 | PNP (0.36) | PNP | |
| SCHEMBL20206650 | 0.84 | PNP (0.36) | PNP | |
| SCHEMBL20202019 | 0.82 | PNP (0.41) | PNPTYMS | |
| SCHEMBL21324597 | 0.82 | PNP (0.41) | PNPTYMS | |
| SCHEMBL19929245 | 0.80 | PNP (0.48) | PNPTYMS | |
| SCHEMBL24231643 | 0.80 | TYMS (0.46) | TYMS | |
| SCHEMBL21325130 | 0.79 | PNP (0.39) | PNPTYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| US-20180148764-A1 | ENZYMATIC MODIFICATION OF NUCLEIC ACIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-05-31 | — | — | US | disclosed |
| US-20180148764-A1 | ENZYMATIC MODIFICATION OF NUCLEIC ACIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | NSUN3, NSUN2, POLRMT | PNP 578/4885TYMS 1058/4885 |
| US-20180148764-A1 | ENZYMATIC MODIFICATION OF NUCLEIC ACIDS | RNGTT, UNG, RNASEL | PNP 41/4885TYMS 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.